Blind 2Stage [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2019-05-30 12:56 (431 d 01:52 ago) – Posting: # 20306
Views: 3,543

Hi Nastia,

» But can you clarify me the meaning of blindness in BE trials?

You know its meaning. ;-)
Never seen ones, except for Health Canada:

2.4.2 Blinding
To avoid study bias, comparative bioavailability studies should be conducted in such a way that the subjects are not aware of which product (test or reference) is being administered.


That’s a funny idea if the products don’t look the same.

» […] it turns out that blinding may even worse the situation (5.01% vs 7.36%, TIE). It is connected with the unknown PE (cause for BLIND=TRUE s20s<-mses), but isn't it contrintuitive?

Yes and yes. Have a look at Figure 1 of Golkowski et al.*

» Can it be true for parallel design also? Suppose we want to make a blind interim analyses after first stage with N subjects and recalculate sample size on fixed GMR=0.95 if total CV would be greater than initial suggestion. Will it cause any inflation?

Possibly.

» How to estimate it?

Simulations… Might be tricky cause we have to think about unequal group sizes and/or variances.

BTW, do you remember Paola Coppola’s presentation at last year’s BioBridges?

[image]




Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
20,963 posts in 4,373 threads, 1,459 registered users;
online 13 (0 registered, 13 guests [including 5 identified bots]).
Forum time: Monday 14:48 CEST (Europe/Vienna)

Garbage in, garbage out.
It’s very very simple.    Anders Fuglsang

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5